In this issue... our share tips for May 2024, the latest on our Aggressive Portfolio IX, plus company features and market insight.
Looking for recovery
Shares in the life sciences and drug discovery company Avacta (41.75p) have fallen significantly since early last year when the share price hit 186p. Whilst hindsight is a wonderful thing, it is clear that the shares were seriously overvalued at that time, although it can also be argued that the decline since then has been overdone. Although the company is some way off profitability, the share price is influenced by other factors such as news on the drug discovery programme and partnership agreements with third parties.
Avacta operates through two divisions. The clinical stage oncology biotech division uses its proprietary therapeutic platforms to develop…
CONTINUED IN THE FULL NEWSLETTER CLICK TO READ
